The content on this site is intended for healthcare professionals only
Prof Lajos Pusztai speaks to ecancer about the results from the I-SPY 2 trial evaluating durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer.
He explains that the olaparib plus durvalumab arm of the trial posed the question of whether it was possible to improve the PCR by adding these drugs to standard of care chemotherapy.
Prof Pusztai reports that the final predicted PCR was higher in all three HER2 negative groups when olaparib and durvalumab was added.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ASCO 2024: Lung cancer highlights
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert round up July 28th to August 3rd, 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
Treatment decision guided by CTC count may improve long-term outcomes for mBC
